Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16465403 | 0.94 | SYK (0.82) | SYK | |
| SCHEMBL8735495 | 0.92 | SYK (0.80) | SYK | |
| SCHEMBL17076556 | 0.90 | SYK (0.77) | SYK | |
| SCHEMBL763226 | 0.90 | SYK (0.73) | SYK | |
| SCHEMBL16465592 | 0.89 | SYK (0.71) | SYK | |
| SCHEMBL16465896 | 0.87 | SYK (0.84) | SYK | |
| SCHEMBL737280 | 0.86 | SYK (1.00) | SYK | |
| SCHEMBL17076531 | 0.85 | SYK (0.81) | SYK | |
| SCHEMBL735011 | 0.85 | SYK (1.00) | SYK | |
| SCHEMBL17076560 | 0.85 | SYK (0.79) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676756-B2 | Substituted pyrimidinyl kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | claimed |
| US-20150259328-A1 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-17 | — | — | US | claimed |
| US-9676756-B2 | Substituted pyrimidinyl kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676756-B2 | Substituted pyrimidinyl kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676756-B2 | Substituted pyrimidinyl kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150259328-A1 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259328-A1 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259328-A1 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259328-A1 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | SYK, JAK2, JAK1 | SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.